Immunovant, Inc. (IMVT) Total Assets by Year
Immunovant, Inc. closed fiscal year 2026 with $957.0M in total assets, $104.4M in total liabilities and $852.6M in shareholder equity. This represents an increase of 23.3% from the prior fiscal year. The table below carries 8 fiscal years, from 2019 to 2026, and the quarters Immunovant, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
IMVT Balance Sheet by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY26DEF 14A | FY25DEF 14A | FY24DEF 14A | FY23DEF 14A | FY22DEF 14A | FY2110-K | FY2010-K | FY1910-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $957.0M+23.3% | $776.2M+16.5% | $666.4M+64.2% | $405.8M-21.3% | $515.6M+25.0% | $412.5M+277.1% | $109.4M+691.1% | $13.8M |
| Total Liabilities | $104.4M+51.8% | $68.8M+41.5% | $48.6M+12.1% | $43.3M-5.2% | $45.7M+117.7% | $21.0M+37.2% | $15.3M+136.1% | $6.5M |
| Total Equity | $852.6M+20.5% | $707.4M+14.5% | $617.8M+70.4% | $362.5M-22.8% | $469.8M+20.0% | $391.5M+316.2% | $94.1M+1181.8% | $7.3M |
IMVT Balance Sheet by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $852.5M+28.9% | $957.0M+23.3% | $1.1B+150.0% | $583.0M+13.0% | $661.4M+12.2% | $776.2M+16.5% | $420.9M-40.8% | $515.7M+76.6% | $589.7M+67.9% | $666.4M+64.2% | $711.4M+55.9% | $292.1M-31.8% |
| Total Liabilities | $117.1M+121.4% | $104.4M+51.8% | $66.3M-3.0% | $63.3M-5.1% | $52.9M+17.5% | $68.8M+41.5% | $68.3M+112.8% | $66.7M+65.6% | $45.0M-12.3% | $48.6M+12.1% | $32.1M-22.8% | $40.3M+24.3% |
| Total Equity | $735.4M+20.8% | $852.6M+20.5% | $986.1M+179.7% | $519.7M+15.7% | $608.5M+11.7% | $707.4M+14.5% | $352.6M-48.1% | $449.1M+78.3% | $544.7M+81.6% | $617.8M+70.4% | $679.3M+63.8% | $251.8M-36.4% |
What total assets means
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders.
More Immunovant, Inc. financials
Frequently Asked Questions
What was Immunovant, Inc.'s total assets in fiscal year 2026?
Immunovant, Inc. closed fiscal year 2026 with $957.0M in total assets, $104.4M in total liabilities and $852.6M in shareholder equity.
How fast is Immunovant, Inc.'s total assets growing?
Immunovant, Inc. (IMVT) total assets rose by 23.3% year over year, from $776.2M to $957.0M in fiscal year 2026.
How has Immunovant, Inc.'s total assets changed over the years?
Across the 8 fiscal years this page covers, Immunovant, Inc. (IMVT) total assets went from $13.8M in fiscal year 2019 to $957.0M in fiscal year 2026.
What was Immunovant, Inc.'s total assets in the most recent quarter?
Immunovant, Inc. (IMVT) reported $852.5M in total assets in Q1 2027. This represents an increase of 28.9% from the same quarter a year earlier.
What does total assets mean on a financial statement?
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders. This page lists what Immunovant, Inc. (IMVT) reported on that line in every period on record.